Published in J Virol on August 01, 1992
Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A (1994) 8.48
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol (2000) 6.71
Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci U S A (1997) 5.76
Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol (1995) 5.43
Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity. J Virol (1992) 4.20
Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J Virol (1993) 4.19
Function of the cytoplasmic domain of a retroviral transmembrane protein: p15E-p2E cleavage activates the membrane fusion capability of the murine leukemia virus Env protein. J Virol (1994) 3.59
Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J Virol (1993) 3.32
A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. J Virol (1995) 3.11
Evidence for a functional interaction between the V1/V2 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp120. J Virol (1994) 3.07
CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. J Virol (1997) 3.04
Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc Natl Acad Sci U S A (1994) 2.88
The energetics of membrane fusion from binding, through hemifusion, pore formation, and pore enlargement. J Membr Biol (2004) 2.59
Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of African origin. J Virol (1995) 2.48
Mutational analysis of the putative fusion domain of Ebola virus glycoprotein. J Virol (1999) 2.41
Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein. J Virol (1993) 2.21
HIV-1 envelope proteins complete their folding into six-helix bundles immediately after fusion pore formation. Mol Biol Cell (2003) 2.18
A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. J Virol (1998) 2.12
HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol (2011) 2.01
Truncations of the simian immunodeficiency virus transmembrane protein confer expanded virus host range by removing a block to virus entry into cells. J Virol (1993) 1.99
Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites. J Virol (2003) 1.95
The amino terminus of Epstein-Barr virus glycoprotein gH is important for fusion with epithelial and B cells. J Virol (2005) 1.70
Mutational analysis of residues in the coiled-coil domain of human immunodeficiency virus type 1 transmembrane protein gp41. J Virol (1998) 1.69
Functional role of the zipper motif region of human immunodeficiency virus type 1 transmembrane protein gp41. J Virol (1994) 1.61
Mutational analysis of the leucine zipper motif in the Newcastle disease virus fusion protein. J Virol (1995) 1.59
Functional importance of the coiled-coil of the Ebola virus glycoprotein. J Virol (2000) 1.59
Identification of a membrane fusion domain and an oligomerization domain in the baculovirus GP64 envelope fusion protein. J Virol (1995) 1.58
Analysis of the cleavage site of the human immunodeficiency virus type 1 glycoprotein: requirement of precursor cleavage for glycoprotein incorporation. J Virol (1995) 1.54
Single-particle cryoelectron microscopy analysis reveals the HIV-1 spike as a tripod structure. Proc Natl Acad Sci U S A (2010) 1.54
Expression and characterization of glycophospholipid-anchored human immunodeficiency virus type 1 envelope glycoproteins. J Virol (1993) 1.47
Complete sequence of enzootic nasal tumor virus, a retrovirus associated with transmissible intranasal tumors of sheep. J Virol (1999) 1.44
Oligomerization of the hydrophobic heptad repeat of gp41. J Virol (1995) 1.38
Structural and functional analysis of interhelical interactions in the human immunodeficiency virus type 1 gp41 envelope glycoprotein by alanine-scanning mutagenesis. J Virol (2001) 1.38
Human immunodeficiency virus type 1 envelope glycoprotein oligomerization requires the gp41 amphipathic alpha-helical/leucine zipper-like sequence. J Virol (1997) 1.31
Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope. J Virol (2003) 1.30
The core of the respiratory syncytial virus fusion protein is a trimeric coiled coil. J Virol (2000) 1.29
A discrete stage of baculovirus GP64-mediated membrane fusion. Mol Biol Cell (1999) 1.25
Biological, molecular, and structural analysis of a cytopathic variant from a molecularly cloned simian immunodeficiency virus. J Virol (1994) 1.24
Inhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion. J Virol (1999) 1.22
Mutational analysis of conserved domains within the cytoplasmic tail of gp41 from human immunodeficiency virus type 1: effects on glycoprotein incorporation and infectivity. J Virol (2000) 1.21
Association of human immunodeficiency virus type 1 envelope glycoprotein with particles depends on interactions between the third variable and conserved regions of gp120. J Virol (1993) 1.20
The second extracellular loop of CXCR4 determines its function as a receptor for feline immunodeficiency virus. J Virol (1998) 1.19
Determinants of human immunodeficiency virus type 1 envelope glycoprotein oligomeric structure. J Virol (1995) 1.19
Amino acid substitutions within the leucine zipper domain of the murine coronavirus spike protein cause defects in oligomerization and the ability to induce cell-to-cell fusion. J Virol (1999) 1.19
Subdomain folding and biological activity of the core structure from human immunodeficiency virus type 1 gp41: implications for viral membrane fusion. J Virol (1999) 1.17
Influence of transmembrane domains on the fusogenic abilities of human and murine leukemia retrovirus envelopes. J Virol (1995) 1.11
Structure-function studies of the self-assembly domain of the human immunodeficiency virus type 1 transmembrane protein gp41. J Virol (2000) 1.10
Palmitoylation of the Rous sarcoma virus transmembrane glycoprotein is required for protein stability and virus infectivity. J Virol (2001) 1.09
The ectodomain of the human T-cell leukemia virus type 1 TM glycoprotein is involved in postfusion events. J Virol (1997) 1.08
Biophysical characterization of recombinant proteins expressing the leucine zipper-like domain of the human immunodeficiency virus type 1 transmembrane protein gp41. J Virol (1996) 1.07
Virus receptors: implications for pathogenesis and the design of antiviral agents. Clin Microbiol Rev (1995) 1.07
Expanded host cell tropism and cytopathic properties of feline immunodeficiency virus strain PPR subsequent to passage through interleukin-2-independent T cells. J Virol (2000) 1.07
Retention of the human immunodeficiency virus type 1 envelope glycoprotein in the endoplasmic reticulum does not redirect virus assembly from the plasma membrane. J Virol (1998) 1.05
Adaptation of human immunodeficiency virus type 1 to cells expressing a binding-deficient CD4 mutant (lysine 46 to aspartic acid). J Virol (1995) 1.03
Variable sensitivity to substitutions in the N-terminal heptad repeat of Mason-Pfizer monkey virus transmembrane protein. J Virol (2003) 1.02
Mutations in the leucine zipper-like heptad repeat sequence of human immunodeficiency virus type 1 gp41 dominantly interfere with wild-type virus infectivity. J Virol (1998) 1.00
Spring-loaded heptad repeat residues regulate the expression and activation of paramyxovirus fusion protein. J Virol (2007) 0.99
A tyrosine motif in the cytoplasmic domain of mason-pfizer monkey virus is essential for the incorporation of glycoprotein into virions. J Virol (2003) 0.99
Inhibition of human and simian immunodeficiency virus protease function by targeting Vpx-protease-mutant fusion protein into viral particles. J Virol (1996) 0.96
Human immunodeficiency virus type 1 and 2 envelope glycoproteins oligomerize through conserved sequences. J Virol (1997) 0.95
Role of the simian virus 5 fusion protein N-terminal coiled-coil domain in folding and promotion of membrane fusion. J Virol (2005) 0.94
C-terminal tail of human immunodeficiency virus gp41: functionally rich and structurally enigmatic. J Gen Virol (2012) 0.93
gp120-independent fusion mediated by the human immunodeficiency virus type 1 gp41 envelope glycoprotein: a reassessment. J Virol (1994) 0.92
Mutational analysis of the oligomer assembly domain in the transmembrane subunit of the Rous sarcoma virus glycoprotein. J Virol (1997) 0.91
Expression of the TM protein of Rous sarcoma virus in the absence of SU shows that this domain is capable of oligomerization and intracellular transport. J Virol (1994) 0.91
Analysis of functional conservation in the surface and transmembrane glycoprotein subunits of human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2. J Virol (1998) 0.89
N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus. Virology (2007) 0.89
Complementation of diverse HIV-1 Env defects through cooperative subunit interactions: a general property of the functional trimer. Retrovirology (2009) 0.88
Homomeric interactions between transmembrane proteins of Moloney murine leukemia virus. J Virol (1996) 0.87
Amino acid residues in the cytoplasmic domain of the Mason-Pfizer monkey virus glycoprotein critical for its incorporation into virions. J Virol (2005) 0.86
The C terminus of the B5 receptor for herpes simplex virus contains a functional region important for infection. J Virol (2005) 0.85
Mutations within a putative cysteine loop of the transmembrane protein of an attenuated immunodeficiency-inducing feline leukemia virus variant inhibit envelope protein processing. J Virol (1995) 0.84
Bioinformatic analysis of HIV-1 entry and pathogenesis. Curr HIV Res (2014) 0.83
Mapping of receptor binding domains in the envelope protein of spleen necrosis virus. J Virol (1995) 0.83
Mutational analysis of the envelope protein of spleen necrosis virus. J Virol (1996) 0.82
Computer-Aided Approaches for Targeting HIVgp41. Biology (Basel) (2012) 0.82
Discovery of novel targets for multi-epitope vaccines: screening of HIV-1 genomes using association rule mining. Retrovirology (2009) 0.81
Identification of a domain within the human T-cell leukemia virus type 2 envelope required for syncytium induction and replication. J Virol (1998) 0.81
Characterization of HIV-1 envelope gp41 genetic diversity and functional domains following perinatal transmission. Retrovirology (2006) 0.81
Activity of the Mason-Pfizer monkey virus fusion protein is modulated by single amino acids in the cytoplasmic tail. J Virol (2005) 0.80
Enhanced in vitro human immunodeficiency virus type 1 replication in B cells expressing surface antibody to the TM Env protein. J Virol (1994) 0.77
Early assembly step of a retroviral envelope glycoprotein: analysis using a dominant negative assay. J Cell Biol (1999) 0.77
Mutation-directed chemical cross-linking of human immunodeficiency virus type 1 gp41 oligomers. J Virol (1998) 0.76
The Membrane-Proximal Region of C-C Chemokine Receptor Type 5 Participates in the Infection of HIV-1. Front Immunol (2017) 0.75
High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol (1987) 43.61
The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. Science (1988) 27.01
Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature (1981) 24.17
The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell (1986) 22.26
Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science (1987) 13.52
In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J Virol (1988) 12.52
The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem (1987) 11.99
X-ray structure of the GCN4 leucine zipper, a two-stranded, parallel coiled coil. Science (1991) 10.81
Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med (1991) 9.28
Expression of wild-type and mutant forms of influenza hemagglutinin: the role of folding in intracellular transport. Cell (1986) 9.16
Evidence that the leucine zipper is a coiled coil. Science (1989) 8.00
The role of the leucine zipper in the fos-jun interaction. Nature (1988) 7.44
A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res Hum Retroviruses (1989) 7.34
Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160. Proc Natl Acad Sci U S A (1988) 6.33
Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature (1983) 5.56
Oligomerization is essential for transport of vesicular stomatitis viral glycoprotein to the cell surface. Cell (1986) 5.19
Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus. Cell (1987) 4.84
Fusion mutants of the influenza virus hemagglutinin glycoprotein. Cell (1985) 4.84
Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci U S A (1990) 4.46
Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain. J Virol (1991) 4.37
Infectious mutants of HTLV-III with changes in the 3' region and markedly reduced cytopathic effects. Science (1986) 4.17
Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1. J Virol (1989) 4.07
Human immunodeficiency virus infection of CD4-bearing cells occurs by a pH-independent mechanism. EMBO J (1988) 3.98
Folding, trimerization, and transport are sequential events in the biogenesis of influenza virus hemagglutinin. Cell (1988) 3.73
Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins. J Gen Virol (1990) 3.59
Oligomeric structure of a prototype retrovirus glycoprotein. Proc Natl Acad Sci U S A (1988) 3.06
Changes in the transmembrane region of the human immunodeficiency virus type 1 gp41 envelope glycoprotein affect membrane fusion. J Virol (1990) 2.95
Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene. Cell (1988) 2.91
Studies with crosslinking reagents on the oligomeric structure of the env glycoprotein of HIV. Virology (1989) 2.74
Functional interaction of constant and variable domains of human immunodeficiency virus type 1 gp120. J Virol (1989) 2.60
Retroviral envelope glycoproteins contain a "leucine zipper"-like repeat. AIDS Res Hum Retroviruses (1990) 2.24
Alteration of the pH dependence of coronavirus-induced cell fusion: effect of mutations in the spike glycoprotein. J Virol (1991) 2.16
Fos-Jun interaction: mutational analysis of the leucine zipper domain of both proteins. Genes Dev (1989) 2.06
Mutations within the human immunodeficiency virus type 1 gp160 envelope glycoprotein alter its intracellular transport and processing. Virology (1991) 2.05
Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles. J Virol (1990) 2.00
Evidence from studies with a cross-linking reagent that the haemagglutinin of influenza virus is a trimer. Virology (1977) 1.93
Leucine zipper motif extends. Nature (1989) 1.88
Characterization of a putative cellular receptor for HIV-1 transmembrane glycoprotein using synthetic peptides. AIDS (1990) 1.77
Oligomerization of glycolipid-anchored and soluble forms of the vesicular stomatitis virus glycoprotein. J Virol (1989) 1.64
X-ray scattering indicates that the leucine zipper is a coiled coil. Proc Natl Acad Sci U S A (1991) 1.51
V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity. Virology (1992) 1.35
Transport of membrane proteins to the cell surface. Curr Top Microbiol Immunol (1991) 1.06
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med (1998) 8.62
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol (2000) 6.71
Nucleotide sequence of Mason-Pfizer monkey virus: an immunosuppressive D-type retrovirus. Cell (1986) 6.07
Myristylation is required for intracellular transport but not for assembly of D-type retrovirus capsids. J Virol (1987) 5.68
A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent. Proc Natl Acad Sci U S A (1994) 4.43
Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity. J Virol (1992) 4.20
A single amino acid substitution within the matrix protein of a type D retrovirus converts its morphogenesis to that of a type C retrovirus. Cell (1990) 3.70
A proline-rich motif (PPPY) in the Gag polyprotein of Mason-Pfizer monkey virus plays a maturation-independent role in virion release. J Virol (1998) 3.69
Mutants of the Rous sarcoma virus envelope glycoprotein that lack the transmembrane anchor and cytoplasmic domains: analysis of intracellular transport and assembly into virions. J Virol (1987) 3.28
Human immunodeficiency virus envelope protein determines the site of virus release in polarized epithelial cells. Proc Natl Acad Sci U S A (1991) 3.18
Mutations of the Rous sarcoma virus env gene that affect the transport and subcellular location of the glycoprotein products. J Cell Biol (1984) 3.11
Oligomeric structure of a prototype retrovirus glycoprotein. Proc Natl Acad Sci U S A (1988) 3.06
Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc Natl Acad Sci U S A (1994) 2.88
Setting standards of prescribing performance in primary care: use of a consensus group of general practitioners and application of standards to practices in the north of England. Br J Gen Pract (1996) 2.75
Mutational analysis of the major homology region of Mason-Pfizer monkey virus by use of saturation mutagenesis. J Virol (1992) 2.56
Complete sequence of the Rous sarcoma virus env gene: identification of structural and functional regions of its product. J Virol (1983) 2.53
Amino acid substitutions within the matrix protein of type D retroviruses affect assembly, transport and membrane association of a capsid. EMBO J (1991) 2.51
Preassembled capsids of type D retroviruses contain a signal sufficient for targeting specifically to the plasma membrane. J Virol (1990) 2.51
Amino acids encoded downstream of gag are not required by Rous sarcoma virus protease during gag-mediated assembly. J Virol (1991) 2.38
Structural role of the matrix protein of type D retroviruses in gag polyprotein stability and capsid assembly. J Virol (1990) 2.34
Psychological and social evaluation in cases of deliberate self-poisoning seen in an accident department. Br Med J (Clin Res Ed) (1982) 2.29
Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein. EMBO J (1997) 2.23
Cancer-related risk indicators and preventive screening behaviors among lesbians and bisexual women. Am J Public Health (2001) 2.18
From veterinary student to professor to private practitioner. J Am Vet Med Assoc (1991) 2.18
A prescribing incentive scheme for non-fundholding general practices: an observational study. BMJ (1996) 2.09
Mutations within the proteolytic cleavage site of the Rous sarcoma virus glycoprotein that block processing to gp85 and gp37. J Virol (1987) 2.07
Truncations of the simian immunodeficiency virus transmembrane protein confer expanded virus host range by removing a block to virus entry into cells. J Virol (1993) 1.99
Postassembly cleavage of a retroviral glycoprotein cytoplasmic domain removes a necessary incorporation signal and activates fusion activity. J Virol (1994) 1.97
Immunoglobulin synthesis and generalized autoimmunity in mice congenitally deficient in alpha beta(+) T cells. Nature (1994) 1.94
Arterial blood pressure responses to graded transient arousal from sleep in normal humans. J Appl Physiol (1985) (1993) 1.89
Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. J Virol (1999) 1.89
Synthesis and assembly of retrovirus Gag precursors into immature capsids in vitro. J Virol (1996) 1.85
Polypeptides of Mason-Pfizer monkey virus. I. Synthesis and processing of the gag-gene products. Virology (1984) 1.83
A viral protease-mediated cleavage of the transmembrane glycoprotein of Mason-Pfizer monkey virus can be suppressed by mutations within the matrix protein. Proc Natl Acad Sci U S A (1992) 1.83
Efficient in vivo and in vitro assembly of retroviral capsids from Gag precursor proteins expressed in bacteria. J Virol (1995) 1.81
Deaths from ischaemic heart disease and infant mortality in England and Wales. J Epidemiol Community Health (1979) 1.81
A chimeric avian retrovirus containing the influenza virus hemagglutinin gene has an expanded host range. J Virol (1992) 1.80
Distinct subsets of retroviruses encode dUTPase. J Virol (1992) 1.80
Medical ethics education: past, present, and future. Acad Med (1995) 1.79
Ethical dilemmas in hyperbaric medicine. Undersea Hyperb Med (2001) 1.78
Members oppose AVMA's guidelines for alternative and complementary veterinary medicine. J Am Vet Med Assoc (1996) 1.77
The primary effect of the Ity locus is on the rate of growth of Salmonella typhimurium that are relatively protected from killing. J Immunol (1990) 1.71
Avian reticuloendotheliosis viruses: evolutionary linkage with mammalian type C retroviruses. J Virol (1979) 1.68
The mechanism for genetic recombination in the avian retroviruses. Curr Top Microbiol Immunol (1978) 1.67
Biological techniques for avian sarcoma viruses. Methods Enzymol (1979) 1.67
Appropriate prescribing in asthma. PACT data have drawbacks. BMJ (1995) 1.61
Mastitis control program: effect on milk production. J Dairy Sci (1972) 1.57
Analysis of the cleavage site of the human immunodeficiency virus type 1 glycoprotein: requirement of precursor cleavage for glycoprotein incorporation. J Virol (1995) 1.54
A psychometric analysis of the measurement level of the rating scale, time trade-off, and standard gamble. Soc Sci Med (2001) 1.51
A charged amino acid substitution within the transmembrane anchor of the Rous sarcoma virus envelope glycoprotein affects surface expression but not intracellular transport. J Cell Biol (1987) 1.50
Mutations within the proteolytic cleavage site of the Rous sarcoma virus glycoprotein define a requirement for dibasic residues for intracellular cleavage. J Virol (1992) 1.50
Expression and characterization of glycophospholipid-anchored human immunodeficiency virus type 1 envelope glycoproteins. J Virol (1993) 1.47
Effect of retroviral proteinase inhibitors on Mason-Pfizer monkey virus maturation and transmembrane glycoprotein cleavage. J Virol (1992) 1.46
Amino-terminal amino acid sequence of the major structural polypeptides of avian retroviruses: sequence homology between reticuloendotheliosis virus p30 and p30s of mammalian retroviruses. Proc Natl Acad Sci U S A (1978) 1.46
AIDS biosafety. Science (1991) 1.44
Pausing of reverse transcriptase on retroviral RNA templates is influenced by secondary structures both 5' and 3' of the catalytic site. Nucleic Acids Res (1998) 1.43
Inhibition of Rous sarcoma virus replication by 2-deoxyglucose and tunicamycin: identification of an unglycosylated env gene product. J Virol (1979) 1.42
Models for predicting prescribing costs in general practice should use per capita practice costs and not total practice costs. Pharmacoepidemiol Drug Saf (1998) 1.40
Functional analysis of the core human immunodeficiency virus type 1 packaging signal in a permissive cell line. J Virol (1998) 1.38
Oligomerization of the hydrophobic heptad repeat of gp41. J Virol (1995) 1.38
Effect of cloned human interferons on protein synthesis and morphogenesis of herpes simplex virus. J Virol (1985) 1.38
More comments on bovine somatotropin. J Am Vet Med Assoc (1994) 1.36
Human immunodeficiency virus type 1 envelope glycoprotein is modified by O-linked oligosaccharides. J Virol (1994) 1.35
V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity. Virology (1992) 1.35
Identification of a cytoplasmic targeting/retention signal in a retroviral Gag polyprotein. J Virol (1999) 1.33
An avian sarcoma virus mutant that is temperature sensitive for virion assembly. Virology (1976) 1.33
Alterations in the transport and processing of Rous sarcoma virus envelope glycoproteins mutated in the signal and anchor regions. J Cell Biochem (1983) 1.31
Stochastic complexity measures for physiological signal analysis. IEEE Trans Biomed Eng (1998) 1.27
Type D retrovirus capsid assembly and release are active events requiring ATP. J Virol (1998) 1.22
Amino-terminal deletion mutants of the Rous sarcoma virus glycoprotein do not block signal peptide cleavage but can block intracellular transport. J Cell Biol (1986) 1.21
Mutational analysis of conserved domains within the cytoplasmic tail of gp41 from human immunodeficiency virus type 1: effects on glycoprotein incorporation and infectivity. J Virol (2000) 1.21
Molecular cloning of the wild-type phoM operon in Escherichia coli K-12. J Bacteriol (1988) 1.20
Lymphocyte proliferation in mice congenitally deficient in T-cell receptor alpha beta + cells. Proc Natl Acad Sci U S A (1994) 1.20
A rapid screening procedure for the isolation of nonconditional replication mutants of Mason-Pfizer monkey virus: identification of a mutant defective in pol. Virology (1985) 1.19
Importance of p12 protein in Mason-Pfizer monkey virus assembly and infectivity. J Virol (1992) 1.19
Absence of two membrane proteins containing extracellular thiol groups in Rhnull human erythrocytes. Biochem J (1983) 1.18
Expression of the Rous sarcoma virus env gene from a simian virus 40 late-region replacement vector: effects of upstream initiation codons. J Virol (1987) 1.18
Alignment of the peptides derived from acid-catalyzed cleavage of an aspartylprolyl bond in the major internal structural polypeptide of avian retroviruses. J Biol Chem (1980) 1.17
Molecular events in the assembly of retrovirus particles. Adv Exp Med Biol (1998) 1.16
T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine. J Immunol (1989) 1.15
Type D retrovirus Gag polyprotein interacts with the cytosolic chaperonin TRiC. J Virol (2001) 1.14
Identification and Origin of Xanthomonas campestris pv. campestris Races and Related Pathovars. Phytopathology (2001) 1.14
Separate assembly and transport domains within the Gag precursor of Mason-Pfizer monkey virus. J Virol (1999) 1.13
Consultation-liaison scheme for self-poisoned patients in a general hospital. Br Med J (1978) 1.13
Dynamic response of murine gut intraepithelial T cells after infection by the coccidian parasite Eimeria. Eur J Immunol (1993) 1.13
Can otolith elemental chemistry retrospectively track migrations in fully marine fishes? J Fish Biol (2012) 1.12
Mutations within the env gene of Mason-Pfizer monkey virus: effects on protein transport and SU-TM association. J Virol (1992) 1.12
A trial for comparing methods for eliciting treatment preferences from men with advanced prostate cancer: results from the initial visit. Med Care (2000) 1.11
Immunodeficiency in rhesus monkeys associated with the original Mason-Pfizer monkey virus. J Natl Cancer Inst (1986) 1.11
Concepts and recent developments in mastitis control. J Am Vet Med Assoc (1969) 1.10
Health-related behaviours as predictors of mortality and morbidity in Australian Aborigines. Prev Med (2006) 1.09
Palmitoylation of the Rous sarcoma virus transmembrane glycoprotein is required for protein stability and virus infectivity. J Virol (2001) 1.09